hereditary transthyretin amyloidosis market
Nov 26, 2024
FDA Grants Orphan Drug Designation for Ractigen’s RAG-21 in ALS; Intellia’s Nexiguran RMAT for ATTR Amyloidosis; FDA Approves Acoramidis for ATTR-CM; Jazz Wins FDA Approval for Ziihera in HER2-Positive Biliary Cancer; J&J Seeks FDA Approval for Subcutaneous TREMFYA in Colitis
Ractigen Therapeutics Receives FDA Orphan Drug Designation for RAG-21 to Treat ALS Ractigen Therapeutics has announced that the FDA has granted Orphan Drug Designation (ODD) to RAG-21, its novel siRNA therapy for treating amyotrophic lateral sclerosis (ALS). RAG-21 specifically targets FUS-ALS, one of the most a...
Read More...
Aug 07, 2020
Unfolding The Folds Of Transthyretin
The Hereditary Transthyretin Amyloidosis (hATTR) Market size in the 7MM was estimated to be USD 306.9 Million in 2017 and is anticipated to grow further in the forecast period 2020-30 owing to recent approvals and pipeline therapies.Among the 7MM geographies, the US accounted for the 54% share of the total hATTR ma...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
